Physician profile
John W Thomas
NPI 1881857498
$3,449.18
in general payments reported to CMS, 2019-2025
30 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $450 · 2021: $648 · 2022: $416 · 2023: $680 · 2024: $374 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $457.23 | 2019-2022 | |
| Lilly USA, LLC | $369.80 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $297.54 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $167.03 | 2021-2025 | |
| Amarin Pharma, INC. | $153.19 | 2019-2021 | |
| Sanofi Pasteur INC. | $136.58 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.73 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $130.28 | 2019-2023 | Farxiga |
| Amgen INC. | $116.99 | 2019-2025 | Evenity, Prolia |
| Eisai INC. | $104.93 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $100.86 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $92.65 | 2022-2025 | Rexulti |
| Pfizer INC. | $89.90 | 2020-2025 | |
| Biogen, INC. | $78.27 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.15 | 2019-2023 | Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $55.02 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $37.09 | 2021 | |
| Allergan, INC. | $30.26 | 2020 | |
| Dexcom, INC. | $23.75 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $21.81 | 2025 | Vaxelis, Vaxneuvance, Enflonsia |
| Averitas Pharma INC. | $21.53 | 2023 | Qutenza |
| Covidien LP | $21.41 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.25 | 2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.91 | 2023 | |
| Exact Sciences Corporation | $16.62 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $16.54 | 2021 | |
| Paratek Pharmaceuticals, INC. | $15.00 | 2024 | Nuzyra |
| Esperion Therapeutics, INC. | $14.72 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.